Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
46°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Personalis, Inc.
< Previous
1
2
3
Next >
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
November 30, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
November 21, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
October 31, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Third Quarter 2022 Financial Results
October 19, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
October 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
August 30, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
August 17, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
August 15, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
August 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Second Quarter 2022 Financial Results
August 03, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 02, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Second Quarter 2022 Financial Results
July 20, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
July 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports First Quarter 2022 Financial Results
May 04, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at Upcoming Investor Conferences
April 28, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
April 21, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce First Quarter 2022 Financial Results
April 20, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
April 12, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022
April 11, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
March 31, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
March 24, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
March 23, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
February 24, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Present at the Cowen 42nd Annual Health Care Conference
February 23, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
February 15, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
Personalis to Announce Fourth Quarter and Full-Year Financial Results
February 10, 2022
From
Personalis, Inc.
Via
Business Wire
Tickers
PSNL
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.